https://www.selleckchem.com/products/cp-43.html
for SES. Accurate assessments of patient response to therapy are a critical component of personalized medicine. In glioblastoma (GBM), the most aggressive form of brain cancer, tumor growth dynamics are heterogenous across patients, complicating assessment of treatment response. This study aimed to analyze days gained (DG), a burgeoning model-based dynamic metric, for response assessment in patients with recurrent GBM who received bevacizumab-based therapies. DG response scores were calculated using volumetric tumor segmentations for pati
Kao
Komentar
Udio
